The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
GSK Partners with Muna Therapeutics to Advance Alzheimer's Drug Development
Muna Therapeutics has partnered with GSK to explore new Alzheimer’s drug targets by analyzing brain tissue samples from various sources, including healthy individuals and Alzheimer’s patients. GSK will invest €33.5 million upfront, with potential milestone payments of up to €140 million for each target identified. This collaboration marks GSK's renewed focus on neuroscience after a decade-long hiatus, leveraging Muna's technology to advance drug development in neurodegenerative diseases.
GSK reports positive Phase 3 results for chronic nasal condition drug
GSK announced positive results from two Phase 3 trials of its antibody drug depemokimab for chronic rhinosinusitis with nasal polyps (CRSwNP), showing significant suppression of nasal polyp growth and improved nasal obstruction compared to placebo. The drug, which targets IL-5, is also being studied for asthma and other inflammatory diseases, with potential peak annual sales exceeding £3 billion if approved. Detailed trial results will be presented at an upcoming scientific congress.